After 14 months of iteration, our lab has stable red macroalgae lines with targeted glycosylation edits that boost 2-O/6-O sulfation and yield a heparin-like polysaccharide showing sub-micromolar anti-thrombin activity in vitro. For those with experience moving marine biopharmaceuticals toward IND, are you seeing regulators favor closed photobioreactor cultivation over offshore farming for consistent GMP-grade polysaccharides, and how are you handling lot-to-lot sulfation profiling at scale?